Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705819 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory Evaluation of [11C]-NOP46
A Early Phase 1 study of Chronic Pain, sponsored by Columbia University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03705819: Completed Early Phase 1 study of Chronic Pain, sponsored by Columbia University.
NCT03705819 is a Early Phase 1 study of Chronic Pain that has completed, run by Columbia University. The registered enrollment target is 10 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705819, a Early Phase 1 study of Chronic Pain, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10µg) of \[11C\]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of \[11C\]-NOP46 followed by PET/CT of region of interests.
Primary Outcome
The uptake ratio for the site with pain to the site without pain is greater than 1 in the focal pain subjects
Conditions Studied
Interventions
- DRUG [11C]-NOP46
- RADIATION PET/CT scan
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-10-30 |
| Phase | Early Phase 1 |
What the finished NCT03705819 record still lists
NCT03705819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which [11C]-NOP46 is the first listed.
NCT03705819 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03705819 about?
NCT03705819 is a clinical study titled "Exploratory Evaluation of [11C]-NOP46". This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10µg) of \[11C\]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluati...
What is the current status of trial NCT03705819?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-03-25. Estimated completion is 2023-10-30.
What conditions does trial NCT03705819 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT03705819?
The interventions under investigation include: [11C]-NOP46 (DRUG), PET/CT scan (RADIATION).
Who is sponsoring clinical trial NCT03705819?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03705819 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03705819's enrollment target sits among peer trials
10 292nd of 301 higher than 4 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol in Opioid Use Disorder and Chronic Pain
RECRUITING · Early Phase 1
-
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
-
Immunologic Response to Negative Cognition in Persons With Chronic Pain
COMPLETED · Early Phase 1
-
Managing Chronic Pain in Veterans With Substance Use Disorders
COMPLETED · Early Phase 1
-
Non-Opioid Pramipexole and Pain
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI